Status:
COMPLETED
Phase 3 Papulopustular Rosacea Study
Lead Sponsor:
Galderma R&D
Conditions:
Papulopustular Rosacea
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to demonstrate that CD5024 1% cream is more effective than its vehicle when applied once daily, at bed time, during a 12 week period in subjects with Papulopustular Rosace...
Eligibility Criteria
Inclusion
- The subject has papulopustular rosacea with an Investigator Global Assessment (IGA) score rated 3 (moderate) or 4 (severe),
- The subject has at least 15 but not more than 70 inflammatory lesions (papules and pustules) on the face.
Exclusion
- The subject has particular forms of rosacea (rosacea conglobata, rosacea fulminans, isolated rhinophyma, isolated pustulosis of the chin) or other facial dermatoses that may be confounded with papulopustular rosacea, such as peri oral dermatitis, facial keratosis pilaris, seborrheic dermatitis, and acne,
- The subject has rosacea with more than two nodules on the face.
Key Trial Info
Start Date :
December 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2013
Estimated Enrollment :
688 Patients enrolled
Trial Details
Trial ID
NCT01494467
Start Date
December 1 2011
End Date
August 1 2013
Last Update
February 18 2021
Active Locations (50)
Enter a location and click search to find clinical trials sorted by distance.
1
Total Skin and Beauty
Birmingham, Alabama, United States, 35205
2
Coastal Clinical Research, Inc.
Mobile, Alabama, United States, 36608
3
Burke Pharmaceutical Research
Hot Springs, Arkansas, United States, 71913
4
Dermatology Specialists, Inc
Oceanside, California, United States, 92056